In this review we examine, in the context of the amyloid, tau, and neurodegeneration framework, the available evidence and potential alternatives on how to establish tau positivity (T+) for multiple tau-imaging tracers in order to reach a consensus on normal and abnormal tau imaging values that can be universally implemented in clinical research and therapeutic trials.
Keywords: AT(N) framework; Alzheimer disease; biomarkers; brain imaging; tau imaging.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.